T. Rowe Price Associates’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.23B | Buy |
6,297,987
+830
| +0% | +$161K | 0.14% | 137 |
|
|
2025
Q4 | $1.09B | Sell |
6,297,157
-708,833
| -10% | -$129M | 0.12% | 147 |
|
|
2025
Q3 | $1.34B | Sell |
7,005,990
-188,707
| -3% | -$33.5M | 0.14% | 124 |
|
|
2025
Q2 | $1.29B | Buy |
7,194,697
+1,210,459
| +20% | +$210M | 0.15% | 137 |
|
|
2025
Q1 | $1.01B | Buy |
5,984,238
+493,960
| +9% | +$81.1M | 0.12% | 163 |
|
|
2024
Q4 | $828M | Buy |
5,490,278
+1,637,525
| +43% | +$255M | 0.1% | 191 |
|
|
2024
Q3 | $598M | Buy |
3,852,753
+3,697,500
| +2,382% | +$552M | 0.07% | 252 |
|
|
2024
Q2 | $21.3M | Buy |
155,253
+2,869
| +2% | +$393K | ﹤0.01% | 953 |
|
|
2024
Q1 | $20.3M | Sell |
152,384
-2,451,774
| -94% | -$318M | ﹤0.01% | 977 |
|
|
2023
Q4 | $359M | Buy |
2,604,158
+396,447
| +18% | +$52.1M | 0.05% | 305 |
|
|
2023
Q3 | $269M | Buy |
2,207,711
+680,883
| +45% | +$90.7M | 0.04% | 337 |
|
|
2023
Q2 | $215M | Buy |
1,526,828
+1,376,308
| +914% | +$190M | 0.03% | 384 |
|
|
2023
Q1 | $21.3M | Sell |
150,520
-1,136,976
| -88% | -$163M | ﹤0.01% | 906 |
|
|
2022
Q4 | $201M | Sell |
1,287,496
-405,451
| -24% | -$58.3M | 0.03% | 378 |
|
|
2022
Q3 | $208M | Buy |
1,692,947
+567,417
| +50% | +$74.7M | 0.03% | 351 |
|
|
2022
Q2 | $150M | Buy |
1,125,530
+952,037
| +549% | +$130M | 0.02% | 554 |
|
|
2022
Q1 | $23.7M | Sell |
173,493
-11,297
| -6% | -$1.57M | ﹤0.01% | 1189 |
|
|
2021
Q4 | $32M | Sell |
184,790
-5,376
| -3% | -$818K | ﹤0.01% | 1153 |
|
|
2021
Q3 | $27.6M | Sell |
190,166
-16,731
| -8% | -$2.45M | ﹤0.01% | 1204 |
|
|
2021
Q2 | $27.3M | Sell |
206,897
-8,378
| -4% | -$1.1M | ﹤0.01% | 1226 |
|
|
2021
Q1 | $27.6M | Sell |
215,275
-18,096
| -8% | -$2.23M | ﹤0.01% | 1191 |
|
|
2020
Q4 | $27.8M | Sell |
233,371
-8,590
| -4% | -$1.05M | ﹤0.01% | 1130 |
|
|
2020
Q3 | $27.7M | Sell |
241,961
-10,411
| -4% | -$1.23M | ﹤0.01% | 1064 |
|
|
2020
Q2 | $28.8M | Sell |
252,372
-18,495
| -7% | -$1.96M | ﹤0.01% | 1031 |
|
|
2020
Q1 | $21.8M | Buy |
270,867
+21,018
| +8% | +$2.18M | ﹤0.01% | 1043 |
|
|
2019
Q4 | $26.7M | Buy |
249,849
+1,302
| +0.5% | +$136K | ﹤0.01% | 1096 |
|
|
2019
Q3 | $26.6M | Sell |
248,547
-8,153
| -3% | -$837K | ﹤0.01% | 1066 |
|
|
2019
Q2 | $26.1M | Buy |
256,700
+730
| +0.3% | +$70.1K | ﹤0.01% | 1103 |
|
|
2019
Q1 | $23M | Buy |
255,970
+19,784
| +8% | +$1.71M | ﹤0.01% | 1138 |
|
|
2018
Q4 | $19.7M | Buy |
236,186
+6,310
| +3% | +$592K | ﹤0.01% | 1150 |
|
|
2018
Q3 | $24.8M | Buy |
229,876
+3,574
| +2% | +$392K | ﹤0.01% | 1152 |
|
|
2018
Q2 | $24.9M | Sell |
226,302
-1,250
| -0.5% | -$130K | ﹤0.01% | 1130 |
|
|
2018
Q1 | $22.8M | Sell |
227,552
-7,120
| -3% | -$729K | ﹤0.01% | 1144 |
|
|
2017
Q4 | $23.1M | Sell |
234,672
-13,790
| -6% | -$1.31M | ﹤0.01% | 1141 |
|
|
2017
Q3 | $23.3M | Sell |
248,462
-7,468
| -3% | -$793K | ﹤0.01% | 1128 |
|
|
2017
Q2 | $28.4M | Sell |
255,930
-30,623
| -11% | -$3.24M | 0.01% | 1039 |
|
|
2017
Q1 | $28.1M | Sell |
286,553
-5,287
| -2% | -$504K | 0.01% | 1022 |
|
|
2016
Q4 | $26.8M | Sell |
291,840
-2,240
| -0.8% | -$193K | 0.01% | 1030 |
|
|
2016
Q3 | $24.9M | Sell |
294,080
-6,864
| -2% | -$576K | 0.01% | 1052 |
|
|
2016
Q2 | $24.5M | Sell |
300,944
-3,012,930
| -91% | -$229M | 0.01% | 1028 |
|
|
2016
Q1 | $237M | Buy |
3,313,874
+189,868
| +6% | +$12.7M | 0.05% | 356 |
|
|
2015
Q4 | $222M | Sell |
3,124,006
-8,190
| -0.3% | -$551K | 0.05% | 373 |
|
|
2015
Q3 | $193M | Buy |
3,132,196
+79,430
| +3% | +$5.55M | 0.04% | 418 |
|
|
2015
Q2 | $221M | Sell |
3,052,766
-2,599,650
| -46% | -$192M | 0.05% | 420 |
|
|
2015
Q1 | $434M | Sell |
5,652,416
-1,876,110
| -25% | -$134M | 0.09% | 264 |
|
|
2014
Q4 | $505M | Buy |
7,528,526
+391,145
| +5% | +$24.7M | 0.11% | 225 |
|
|
2014
Q3 | $433M | Buy |
7,137,381
+115,022
| +2% | +$7.09M | 0.09% | 249 |
|
|
2014
Q2 | $412M | Sell |
7,022,359
-910,131
| -11% | -$53.3M | 0.09% | 270 |
|
|
2014
Q1 | $459M | Sell |
7,932,490
-1,383,469
| -15% | -$74.1M | 0.1% | 240 |
|
|
2013
Q4 | $499M | Buy |
9,315,959
+412,410
| +5% | +$24.5M | 0.11% | 213 |
|
|
2013
Q3 | $550M | Buy |
8,903,549
+1,322,745
| +17% | +$79.2M | 0.14% | 194 |
|
|
2013
Q2 | $460M | Buy |
+7,580,804
| New | +$452M | 0.12% | 216 |
|
Other funds holding DGX
VCM
VPM
EIG
T. Rowe Price Associates's DGX Position: Q1 2026 in Review
T. Rowe Price Associates increased its Quest Diagnostics (DGX) stake by 0.01% in Q1 2026, buying an estimated $161K and bringing the position to 6,297,987 shares worth $1.23B. The position accounts for 0.14% of the portfolio, ranked #137.
T. Rowe Price Associates first reported a position in DGX in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.34B in Q3 2025. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- T. Rowe Price Associates held 6,297,987 shares of Quest Diagnostics worth $1.23B as of Q1 2026.
- T. Rowe Price Associates bought 830 Quest Diagnostics shares in Q1 2026, an estimated $161K.
- Quest Diagnostics made up 0.14% of T. Rowe Price Associates's portfolio in Q1 2026, its #137 holding.
- T. Rowe Price Associates first reported a position in Quest Diagnostics in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's Quest Diagnostics position peaked at $1.34B in Q3 2025.
- 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.